FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143635140> ?p ?o ?g. }

• W2143635140 endingPage "105" @default.
• W2143635140 startingPage "99" @default.
• W2143635140 abstract "High levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) are associated with inflammation, atherosclerosis, and coronary heart disease events. In addition, Lp-PLA(2) has been linked to classical markers of endothelial activation, including soluble vascular cell adhesion molecule-1 (sVCAM-1). Although treatment with fenofibrate reduces Lp-PLA(2) mass, it is unclear whether fenofibrate reduces sVCAM-1 levels or whether an association exists between any changes observed in Lp-PLA(2) and sVCAM-1. Concentrations of Lp-PLA(2) mass and sVCAM-1 levels were measured in plasma at baseline and after 3 weeks of fenofibrate treatment (160 mg/d) in 96 hypertriglyceridemic participants of the Genetics of Lipid-lowering Drugs and Diet Network study. Lp-PLA(2) and sVCAM-1 were stratified by tertiles as determined by baseline levels of the respective target. Fenofibrate treatment resulted in a 30.1% mean increase in Lp-PLA(2) mass (P = 0.0003) and a 14.7% mean increase in sVCAM-1 levels (P = 0.0096) but only in tertile1 of either target. In contrast, Lp-PLA(2) mass was reduced by 35.3% (P < 0.0001) in tertile 3. Soluble VCAM-1 levels were significantly reduced by 7.74% (P = 0.0109) and 17.2% (P < 0.0001) in tertiles 2 and 3, respectively. No associations were observed between Lp-PLA(2) and sVCAM-1 at baseline or post-treatment. In conclusion, fenofibrate treatment in hypertriglyceridemic subjects reduced the levels of Lp-PLA(2) mass and sVCAM-1, but only in those with elevated baseline levels of these biomarkers. The greatest reductions in Lp-PLA(2) levels were observed in individuals with Lp-PLA(2) concentrations indicative of increased cardiovascular disease risk (>200 ng/mL)." @default.
• W2143635140 created "2016-06-24" @default.
• W2143635140 creator A5011472777 @default.
• W2143635140 creator A5026873580 @default.
• W2143635140 creator A5030401683 @default.
• W2143635140 creator A5045171279 @default.
• W2143635140 creator A5047374406 @default.
• W2143635140 creator A5073235477 @default.
• W2143635140 creator A5073734270 @default.
• W2143635140 creator A5087548137 @default.
• W2143635140 date "2011-08-01" @default.
• W2143635140 modified "2023-10-13" @default.
• W2143635140 title "Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants" @default.
• W2143635140 cites W1967172800 @default.
• W2143635140 cites W1974147284 @default.
• W2143635140 cites W1976463891 @default.
• W2143635140 cites W1982191008 @default.
• W2143635140 cites W1997203658 @default.
• W2143635140 cites W2008589779 @default.
• W2143635140 cites W2008695819 @default.
• W2143635140 cites W2026020109 @default.
• W2143635140 cites W2036744352 @default.
• W2143635140 cites W2053567685 @default.
• W2143635140 cites W2055834907 @default.
• W2143635140 cites W2061315559 @default.
• W2143635140 cites W2061587443 @default.
• W2143635140 cites W2063220849 @default.
• W2143635140 cites W2063798280 @default.
• W2143635140 cites W2065099374 @default.
• W2143635140 cites W2078890386 @default.
• W2143635140 cites W2083403064 @default.
• W2143635140 cites W2086524291 @default.
• W2143635140 cites W2087608575 @default.
• W2143635140 cites W2093817875 @default.
• W2143635140 cites W2097103756 @default.
• W2143635140 cites W2099992849 @default.
• W2143635140 cites W2100479164 @default.
• W2143635140 cites W2102267426 @default.
• W2143635140 cites W2105003628 @default.
• W2143635140 cites W2105577110 @default.
• W2143635140 cites W2114408062 @default.
• W2143635140 cites W2115603535 @default.
• W2143635140 cites W2117092539 @default.
• W2143635140 cites W2118891066 @default.
• W2143635140 cites W2119382976 @default.
• W2143635140 cites W2131222777 @default.
• W2143635140 cites W2131961680 @default.
• W2143635140 cites W2132016007 @default.
• W2143635140 cites W2136054920 @default.
• W2143635140 cites W2152561082 @default.
• W2143635140 cites W2159962535 @default.
• W2143635140 cites W2198678228 @default.
• W2143635140 cites W2327470041 @default.
• W2143635140 cites W4242963513 @default.
• W2143635140 cites W4247145538 @default.
• W2143635140 doi "https://doi.org/10.1016/j.trsl.2011.01.014" @default.
• W2143635140 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3138503" @default.
• W2143635140 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21757154" @default.
• W2143635140 hasPublicationYear "2011" @default.
• W2143635140 type Work @default.
• W2143635140 sameAs 2143635140 @default.
• W2143635140 citedByCount "6" @default.
• W2143635140 countsByYear W21436351402012 @default.
• W2143635140 countsByYear W21436351402013 @default.
• W2143635140 countsByYear W21436351402015 @default.
• W2143635140 countsByYear W21436351402019 @default.
• W2143635140 countsByYear W21436351402020 @default.
• W2143635140 crossrefType "journal-article" @default.
• W2143635140 hasAuthorship W2143635140A5011472777 @default.
• W2143635140 hasAuthorship W2143635140A5026873580 @default.
• W2143635140 hasAuthorship W2143635140A5030401683 @default.
• W2143635140 hasAuthorship W2143635140A5045171279 @default.
• W2143635140 hasAuthorship W2143635140A5047374406 @default.
• W2143635140 hasAuthorship W2143635140A5073235477 @default.
• W2143635140 hasAuthorship W2143635140A5073734270 @default.
• W2143635140 hasAuthorship W2143635140A5087548137 @default.
• W2143635140 hasBestOaLocation W21436351402 @default.
• W2143635140 hasConcept C126322002 @default.
• W2143635140 hasConcept C134018914 @default.
• W2143635140 hasConcept C2776104379 @default.
• W2143635140 hasConcept C2776914184 @default.
• W2143635140 hasConcept C2777034527 @default.
• W2143635140 hasConcept C2778110834 @default.
• W2143635140 hasConcept C2778163477 @default.
• W2143635140 hasConcept C2780072125 @default.
• W2143635140 hasConcept C2780221984 @default.
• W2143635140 hasConcept C71924100 @default.
• W2143635140 hasConceptScore W2143635140C126322002 @default.
• W2143635140 hasConceptScore W2143635140C134018914 @default.
• W2143635140 hasConceptScore W2143635140C2776104379 @default.
• W2143635140 hasConceptScore W2143635140C2776914184 @default.
• W2143635140 hasConceptScore W2143635140C2777034527 @default.
• W2143635140 hasConceptScore W2143635140C2778110834 @default.
• W2143635140 hasConceptScore W2143635140C2778163477 @default.
• W2143635140 hasConceptScore W2143635140C2780072125 @default.
• W2143635140 hasConceptScore W2143635140C2780221984 @default.
• W2143635140 hasConceptScore W2143635140C71924100 @default.
• W2143635140 hasIssue "2" @default.

• next